Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Number of holders
-
409
-
Total 13F shares, excl. options
-
54,718,539
-
Shares change
-
-1,477,537
-
Total reported value, excl. options
-
$3,071,120,295
-
Value change
-
-$80,853,798
-
Put/Call ratio
-
90%
-
Number of buys
-
149
-
Number of sells
-
-161
-
Price
-
$56.14
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q2 2023
476 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q2 2023.
CRISPR Therapeutics AG - Common Stock (CRSP) has 409 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54,718,539 shares
of 90,438,636 outstanding shares and own 61% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (7,338,447 shares), Capital International Investors (6,069,723 shares), T. Rowe Price Investment Management, Inc. (3,646,582 shares), Nikko Asset Management Americas, Inc. (3,533,357 shares), Sumitomo Mitsui Trust Holdings, Inc. (3,533,357 shares), BlackRock Inc. (2,718,575 shares), FMR LLC (2,091,173 shares), STATE STREET CORP (1,632,473 shares), NEA Management Company, LLC (1,587,854 shares), and VANGUARD GROUP INC (1,531,090 shares).
This table shows the top 409 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.